GlaxoSmithKline is inching toward European approval for albiglutide, winning a recommendation for its latest diabetes contender as the market for similar drugs gets more and more crowded.

…read more

Source: GlaxoSmithKline clears an EU hurdle with its once-delayed GLP-1 diabetes drug